CordenPharma is a global CDMO specializing in the development and manufacturing of pharmaceuticals across diverse therapeutic areas.

Founded in 2006, CordenPharma serves as a premier partner to pharmaceutical and biotechnology companies. With its extensive network of facilities across Europe and the US, the company provides fully integrated solutions from early-stage drug development to large-scale commercial production. Leveraging advanced technologies and expertise, CordenPharma supports complex and fast-growing modalities, including mRNA vaccines, oncology therapeutics, and high-potency compounds.

Key Products and Services

• Active Pharmaceutical Ingredients (APIs): Research, GMP manufacturing, and commercialisation.
• Drug Products: Development, LNP formulations, and regulatory support.
• Specialised Technology Platforms:
  • Peptides
  • Lipids & Carbohydrates (e.g., for mRNA vaccines)
  • Highly Potent & Oncology
  • Injectables
  • Small Molecules

CordenPharma’s robust infrastructure, spanning 11 manufacturing facilities and one R&D lab, underscores its commitment to delivering high-quality, scalable pharmaceutical solutions. The company’s focus on innovation, customer-centric service, and strategic investments ensures its sustained growth as a leader in the pharmaceutical CDMO industry.